Merck collaborates with Acceleration Consortium for AI experimentation
Betsy Goodfellow | December 8, 2023 | News story | Research and Development | AI, Acceleration Consortium, Merck, Pharmacy, experimentation
Merck and the Acceleration Consortium have announced their AI-driven experimentation planner Bayesian Back End (BayBE) is now available open-source on GitHub. This joint initiative is intended to combine Merck’s portfolio of use cases with the Acceleration Consortium’s expertise in self-driving labs.
Alán Aspuru-Guzik, professor of Chemistry and Computer Science at the University of Toronto, Canada, and director of the Acceleration Consortium, commented: “The release and maintenance of open-source code for scientific discovery is imperative for the advancement of self-driving labs. This collaboration moves the needle of multi-stakeholder work in the area of self-driving labs. I am thrilled about our collaboration with Merck on developing and publishing software for AI-assisted experimental planning. As society faces ever-growing challenges, we have no time for science as usual. With this software, we can revolutionise the way experiments are designed and conducted, accelerating discoveries and driving progress in ways we have never imagined before.”
Laura Matz, chief science and technology officer at Merck, added: “This development is a great outcome of our focus on ‘innovation powered by data and digital’. Together with our partners at the Acceleration Consortium, we continue to push productivity with digital tools such as BayBE. Merck continues to invest in digital technologies that can disrupt the healthcare, life science and electronics industries. BayBE unites several advanced technologies under one umbrella and focuses on making them useful for industrial purposes. While it already has many internal use cases, we are excited to share it with a wider community through open source. What started out as a cross-sectorial advancement can now become a cross-industrial one.”
Betsy Goodfellow
Related Content
Sanome’s AI tool gains certification for early detection of hospital infections
Sanome’s MEMORI, an artificial intelligence (AI) medical device that can predict hospital-acquired infections up to …
M42 study highlights positive performance of AI model for tuberculosis screening
Healthcare tech company, M42, has published results from one of the largest real-world studies of …
BioDuro and Atombeat partner to accelerate AI-powered peptide drug discovery
BioDuro and Atombeat have announced a partnership to launch an artificial intelligence (AI)-driven platform designed …
